"Sumatriptan" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A serotonin agonist that acts selectively at 5HT1 receptors. It is used in the treatment of MIGRAINE DISORDERS.
| Descriptor ID |
D018170
|
| MeSH Number(s) |
D02.065.884.750 D02.886.590.700.750 D03.633.100.473.914.907
|
| Concept/Terms |
Sumatriptan- Sumatriptan
- 3-(2-(Dimethylamino)ethyl)-N-methyl-1H-indole-5-methanesulfonamide
|
Below are MeSH descriptors whose meaning is more general than "Sumatriptan".
Below are MeSH descriptors whose meaning is more specific than "Sumatriptan".
This graph shows the total number of publications written about "Sumatriptan" by people in this website by year, and whether "Sumatriptan" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 2 | 0 | 2 |
| 1999 | 1 | 0 | 1 |
| 2000 | 2 | 0 | 2 |
| 2001 | 3 | 0 | 3 |
| 2002 | 1 | 3 | 4 |
| 2003 | 2 | 2 | 4 |
| 2004 | 3 | 1 | 4 |
| 2005 | 2 | 2 | 4 |
| 2006 | 1 | 0 | 1 |
| 2007 | 2 | 0 | 2 |
| 2008 | 3 | 3 | 6 |
| 2010 | 2 | 2 | 4 |
| 2011 | 1 | 0 | 1 |
| 2012 | 4 | 0 | 4 |
| 2013 | 5 | 2 | 7 |
| 2015 | 2 | 2 | 4 |
| 2016 | 0 | 1 | 1 |
| 2017 | 4 | 0 | 4 |
| 2018 | 0 | 2 | 2 |
| 2020 | 0 | 3 | 3 |
| 2021 | 0 | 1 | 1 |
| 2022 | 1 | 1 | 2 |
| 2025 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Sumatriptan" by people in Profiles.
-
Guzman G, Kopruszinski CM, Barber KR, Lillo Vizin RC, Dodick DW, Navratilova E, Porreca F. Chronification of migraine sensitizes to CGRP in male and female mice. Cephalalgia. 2025 Feb; 45(2):3331024251317446.
-
Lipton RB, Dodick DW, Goadsby PJ, Burstein R, Adams AM, Lai J, Yu SY, Finnegan M, Kuang AW, Trugman JM. Efficacy of Ubrogepant in the Acute Treatment of Migraine With Mild Pain vs Moderate or Severe Pain. Neurology. 2022 10 25; 99(17):e1905-e1915.
-
Medrea I, Christie S, Tepper SJ, Thavorn K, Hutton B. Network meta-analysis of therapies for cluster headache: Effects of acute therapies for episodic and chronic cluster. Headache. 2022 04; 62(4):482-511.
-
Ikegami D, Navratilova E, Yue X, Moutal A, Kopruszinski CM, Khanna R, Patwardhan A, Dodick DW, Porreca F. A prolactin-dependent sexually dimorphic mechanism of migraine chronification. Cephalalgia. 2022 03; 42(3):197-208.
-
Kopruszinski CM, Navratilova E, Swiokla J, Dodick DW, Chessell IP, Porreca F. A novel, injury-free rodent model of vulnerability for assessment of acute and preventive therapies reveals temporal contributions of CGRP-receptor activation in migraine-like pain. Cephalalgia. 2021 03; 41(3):305-317.
-
Navratilova E, Behravesh S, Oyarzo J, Dodick DW, Banerjee P, Porreca F. Ubrogepant does not induce latent sensitization in a preclinical model of medication overuse headache. Cephalalgia. 2020 08; 40(9):892-902.
-
Rau JC, Navratilova E, Oyarzo J, Johnson KW, Aurora SK, Schwedt TJ, Dodick DW, Porreca F. Evaluation of LY573144 (lasmiditan) in a preclinical model of medication overuse headache. Cephalalgia. 2020 08; 40(9):903-912.
-
Nation KM, Dodick DW, Navratilova E, Porreca F. Sustained exposure to acute migraine medications combined with repeated noxious stimulation dysregulates descending pain modulatory circuits: Relevance to medication overuse headache. Cephalalgia. 2019 04; 39(5):617-625.
-
Schwedt TJ, Alam A, Reed ML, Fanning KM, Munjal S, Buse DC, Dodick DW, Lipton RB. Factors associated with acute medication overuse in people with migraine: results from the 2017 migraine in America symptoms and treatment (MAST) study. J Headache Pain. 2018 May 24; 19(1):38.
-
Silberstein SD. A review of clinical safety data for sumatriptan nasal powder administered by a breath powered exhalation delivery system in the acute treatment of migraine. Expert Opin Drug Saf. 2018 Jan; 17(1):89-97.